Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2012 Publisher: Mercury Pharma Group Ltd, No. 1 Croydon, 12-16 Addiscombe Road, Croydon CR0 0XT, UK
Eudemine is a peripheral vasodilator and has qualitatively the same effect on blood vessels as benzothiazine compounds, but the effect is more rapid and profound. Unlike benzothiazines, Eudemine is non-diuretic and causes retention of sodium and water. It causes a prompt increase in blood glucose by a direct inhibitory action on the secretion of insulin by the beta cells in the Islets of Langerhans.
Eudemine injection is administered to adults as a rapid intravenous injection at doses of 150mg to 300mg initially for the treatment of severe hypertension or hypertensive crises. Approximately 90% of Eudemine is bound to plasma proteins. Eudemine crosses the placenta and can cause hyperbilirubinaemia and altered carbohydrate metabolism in the foetus and new-born. Eudemine is eliminated from the body primarily through glomerular filtration. Its long serum half-life (20-30 hours) reflects the fact that 90% of the drug in serum is bound to albumin and protected from filtration. In patients with impaired renal function, the serum half-life increases with decreasing creatinine clearance. The serum half-life is at least 3 times longer than its hypotensive action, and, when dosage is repeated at intervals of 4 to 12 hours, there is extensive accumulation in the body.
No further data of relevance.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
